Drug Profile
Research programme: therapeutic antibodies - Adimab/Celgene Corporation
Latest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Adimab; Celgene Corporation
- Developer Adimab
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 20 Aug 2013 Early research in Undefined indication in USA (Parenteral)